Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes.

Fielden J, Leblanc P, Parezanovic C, Sridhar VS, Perkins BA, Cherney DZ, Campbell DJT.

DOI: 10.1111/dme.70463
Published: 2026-09-04
Container: Diabet Med
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/dme.70463,
  title = {Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes.},
  author = {Fielden J and  Leblanc P and  Parezanovic C and  Sridhar VS and  Perkins BA and  Cherney DZ and  Campbell DJT.},
  year = {2026},
  journal = {Diabet Med},
  doi = {10.1111/dme.70463},
  url = {https://doi.org/10.1111/dme.70463}
}

RIS

TY  - JOUR
TI  - Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes.
AU  - Fielden J
AU  -  Leblanc P
AU  -  Parezanovic C
AU  -  Sridhar VS
AU  -  Perkins BA
AU  -  Cherney DZ
AU  -  Campbell DJT.
PY  - 2026
JO  - Diabet Med
DO  - 10.1111/dme.70463
UR  - https://doi.org/10.1111/dme.70463
ER  -

APA

J, F., P, L., C, P., VS, S., BA, P., DZ, C., & DJT., C. (2026). Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes.. Diabet Med. https://doi.org/10.1111/dme.70463

Source records

europe-pmc · retrieved 2026-09-27T01:15:22.316Z